Completed PHASE2 INTERVENTIONAL 3-arm NCT01096472

Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis

Phase IIa, Two-center, Randomized, Double Blind Study With Parallel Groups to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS 41003 Versus Corresponding Mono-substances in Patients With Inflammatory Tinea Pedis

Sponsor: Almirall, S.A.

Conditions Tinea Pedis

Interventions LAS189961 LAS189962 LAS41003

Updated 5 times since 2017 Last updated: Jul 5, 2012 Started: Feb 28, 2010 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01096472, this PHASE2 trial focuses on Tinea Pedis and remains completed. Sponsored by Almirall, S.A., it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Almirall, S.A.

Data source: Almirall, S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany
• Hamburg, Germany